(Q37626774)

21 August 2017

1 reference

title

Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease (English)

1 reference

21 August 2017

0 references

Neil H Shear

1

1 reference

21 August 2017

Jörg Prinz

2

1 reference

21 August 2017

Kim Papp

3

1 reference

21 August 2017

Richard G B Langley

4

1 reference

21 August 2017

Wayne P Gulliver

5

1 reference

21 August 2017

publication date

1 December 2008

1 reference

Journal of cutaneous medicine and surgery

21 August 2017

published in

1 reference

21 August 2017

volume

12 Suppl 1

1 reference

21 August 2017

page(s)

S1-10

1 reference

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

CD4 antibody treatment of severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Comorbidity in older adults: nosology of impairment, diseases, and conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

Long-term prognosis in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310%2F7750.2008%2F08070

21 January 2018

Identifiers

DOI

10.2310/7750.2008/08070

1 reference

21 August 2017

1 reference